SparingVision has raised €75 million in second-round funding that will be used to fund clinical trials of gene therapies for ... visual acuity and colour vision. The current schedule is for ...

Patients in the intermediate stage of the disease currently lack an effective treatment to improve vision or slow disease progression. Now, a new gene therapy from biotech innovator Oculogenex, Inc.

Neurotech Pharmaceuticals’ gene therapy comes in a surgical implant, and it’s now the first FDA-approved treatment for a rare vision-loss disorder. The approval handed out on March 5 covers ...